Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1984 Aug;74(2):341–350. doi: 10.1172/JCI111429

Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium.

J A Marcum, J B McKenney, R D Rosenberg
PMCID: PMC370484  PMID: 6746897

Abstract

We have examined the role of heparinlike molecules in the regulation of coagulation by perfusing rat hindquarters with purified human thrombin and with its plasma inhibitor, antithrombin. Our data indicate that contact of the hemostatic components with the endothelium enhances the rate of thrombin-antithrombin complex formation by as much as 19-fold over the uncatalyzed rate of enzyme-inhibitor interaction. Heparinlike molecules are responsible for the antithrombin accelerating activity. The amount of thrombin-antithrombin complex generated within the hindlimb preparation after pretreatment of the vasculature with purified Flavobacterium heparinase or with addition of platelet Factor IV to the hemostatic components, was equal to the uncatalyzed levels. These heparinlike molecules appear to be tightly bound to the luminal surface of the endothelium, since they could not be detected within the physiologic buffer that was perfused through the animal. The above mucopolysaccharides function in a manner similar to commercial heparin, since modification of antithrombin at a site critical for heparin-dependent acceleration of the protease inhibitor resulted in a level of interaction product identical to the uncatalyzed amount. Finally, addition of diisofluorophosphate-thrombin to the enzyme perfusion stream reduced the amount of thrombin-antithrombin complex formed in the animal by 30-40%, which suggested that thrombin bound to the endothelium as well as enzyme free in solution are accessible to antithrombin that has interacted with heparinlike molecules present on the endothelium.

Full text

PDF
341

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Awbrey B. J., Hoak J. C., Owen W. G. Binding of human thrombin to cultured human endothelial cells. J Biol Chem. 1979 May 25;254(10):4092–4095. [PubMed] [Google Scholar]
  2. Barber A. J., Käser-Glanzmann R., Jakábová M., Lüscher E. F. Characterization of a chondroitin 4 -sulfate proteoglycan carrier for heparin neutralizing activity (platelet factor 4 ) released from human blood platelets. Biochim Biophys Acta. 1972 Dec 29;286(2):312–329. [PubMed] [Google Scholar]
  3. Bauer K. A., Ashenhurst J. B., Chediak J., Rosenberg R. D. Antithrombin "Chicago": a functionally abnormal molecule with increased heparin affinity causing familial thrombophilia. Blood. 1983 Dec;62(6):1242–1250. [PubMed] [Google Scholar]
  4. Blackburn M. N., Sibley C. C. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem. 1980 Feb 10;255(3):824–826. [PubMed] [Google Scholar]
  5. Brown M. S., Deuel T. F., Basu S. K., Goldstein J. L. Inhibition of the binding of low-density lipoprotein to its cell surface receptor in human fibroblasts by positively charged proteins. J Supramol Struct. 1978;8(3):223–234. doi: 10.1002/jss.400080302. [DOI] [PubMed] [Google Scholar]
  6. Buonassisi V., Root M. Enzymatic degradation of heparin-related mucopolysaccharides from the surface of endothelial cell cultures. Biochim Biophys Acta. 1975 Mar 14;385(1):1–10. doi: 10.1016/0304-4165(75)90067-7. [DOI] [PubMed] [Google Scholar]
  7. Busch C., Owen W. G. Identification in vitro of an endothelial cell surface cofactor for antithrombin III. Parallel studies with isolated perfused rat hearts and microcarrier cultures of bovine endothelium. J Clin Invest. 1982 Mar;69(3):726–729. doi: 10.1172/JCI110502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Castellot J. J., Jr, Addonizio M. L., Rosenberg R., Karnovsky M. J. Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J Cell Biol. 1981 Aug;90(2):372–379. doi: 10.1083/jcb.90.2.372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Damus P. S., Hicks M., Rosenberg R. D. Anticoagulant action of heparin. Nature. 1973 Dec 7;246(5432):355–357. doi: 10.1038/246355a0. [DOI] [PubMed] [Google Scholar]
  10. Dvorak H. F., Hammond M. E., Colvin R. B., Manseau E. J., Goodwin J. Systemic expression of cutaneous basophil hypersensitivity. J Immunol. 1977 May;118(5):1549–1557. [PubMed] [Google Scholar]
  11. Galliher P. M., Cooney C. L., Langer R., Linhardt R. J. Heparinase production by Flavobacterium heparinum. Appl Environ Microbiol. 1981 Feb;41(2):360–365. doi: 10.1128/aem.41.2.360-365.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Heemstra V. L. Evidence for serotonin binding in vitro by platelet factor 4 and beta-thromboglobulin. Thromb Res. 1983 Feb 1;29(3):323–332. doi: 10.1016/0049-3848(83)90044-0. [DOI] [PubMed] [Google Scholar]
  13. Highsmith R. F., Rosenberg R. D. A rapid and sensitive proteolytic assay for human plasminogen and plasmin using radioiodinated alpha-casein. Thromb Res. 1977 Aug;11(2):131–140. doi: 10.1016/0049-3848(77)90031-7. [DOI] [PubMed] [Google Scholar]
  14. Hiti-Harper J., Wohl H., Harper E. Platelet factor 4: an inhibitor of collagenase. Science. 1978 Mar 3;199(4332):991–992. doi: 10.1126/science.203038. [DOI] [PubMed] [Google Scholar]
  15. Huang S. S., Huang J. S., Deuel T. F. Proteoglycan carrier of human platelet factor 4. Isolation and characterization. J Biol Chem. 1982 Oct 10;257(19):11546–11550. [PubMed] [Google Scholar]
  16. Jordan R. E., Favreau L. V., Braswell E. H., Rosenberg R. D. Heparin with two binding sites for antithrombin or platelet factor 4. J Biol Chem. 1982 Jan 10;257(1):400–406. [PubMed] [Google Scholar]
  17. Jordan R. E., Oosta G. M., Gardner W. T., Rosenberg R. D. The binding of low molecular weight heparin to hemostatic enzymes. J Biol Chem. 1980 Nov 10;255(21):10073–10080. [PubMed] [Google Scholar]
  18. Jordan R. E., Oosta G. M., Gardner W. T., Rosenberg R. D. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem. 1980 Nov 10;255(21):10081–10090. [PubMed] [Google Scholar]
  19. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  20. Lau H. K., Rosenberg R. D. The isolation and characterization of a specific antibody population directed against the thrombin antithrombin complex. J Biol Chem. 1980 Jun 25;255(12):5885–5893. [PubMed] [Google Scholar]
  21. Lollar P., MacIntosh S. C., Owen W. G. Reaction of antithrombin III with thrombin bound to the vascular endothelium. Analysis in a recirculating perfused rabbit heart preparation. J Biol Chem. 1984 Apr 10;259(7):4335–4338. [PubMed] [Google Scholar]
  22. Lollar P., MacIntosh S., Owen W. G. Interaction of thrombin with the vascular endothelium in a recirculating Langendorff rabbit heart preparation. Ann N Y Acad Sci. 1982;401:234–240. doi: 10.1111/j.1749-6632.1982.tb25722.x. [DOI] [PubMed] [Google Scholar]
  23. Lollar P., Owen W. G. Clearance of thrombin from circulation in rabbits by high-affinity binding sites on endothelium. Possible role in the inactivation of thrombin by antithrombin III. J Clin Invest. 1980 Dec;66(6):1222–1230. doi: 10.1172/JCI109973. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Marcum J. A., Fritze L., Galli S. J., Karp G., Rosenberg R. D. Microvascular heparin-like species with anticoagulant activity. Am J Physiol. 1983 Nov;245(5 Pt 1):H725–H733. doi: 10.1152/ajpheart.1983.245.5.H725. [DOI] [PubMed] [Google Scholar]
  25. Marcum J. A., Rosenberg R. D. Anticoagulantly active heparin-like molecules from vascular tissue. Biochemistry. 1984 Apr 10;23(8):1730–1737. doi: 10.1021/bi00303a023. [DOI] [PubMed] [Google Scholar]
  26. Niewiarowski S., Rucinski B., James P., Lindahl U. Platelet antiheparin proteins and antithrombin III interact with different binding sites on heparin molecule. FEBS Lett. 1979 Jun 1;102(1):75–78. doi: 10.1016/0014-5793(79)80931-x. [DOI] [PubMed] [Google Scholar]
  27. O'Farrell P. Z., Goodman H. M., O'Farrell P. H. High resolution two-dimensional electrophoresis of basic as well as acidic proteins. Cell. 1977 Dec;12(4):1133–1141. doi: 10.1016/0092-8674(77)90176-3. [DOI] [PubMed] [Google Scholar]
  28. Renkin E. M., Gray S. D., Dodd L. R. Filling of microcirculation in skeletal muscles during timed India ink perfusion. Am J Physiol. 1981 Aug;241(2):H174–H186. doi: 10.1152/ajpheart.1981.241.2.H174. [DOI] [PubMed] [Google Scholar]
  29. Rodbard D., Lenox R. H., Wray H. L., Ramseth D. Statistical characterization of the random errors in the radioimmunoassay dose--response variable. Clin Chem. 1976 Mar;22(3):350–358. [PubMed] [Google Scholar]
  30. Rodbard D. Statistical quality control and routine data processing for radioimmunoassays and immunoradiometric assays. Clin Chem. 1974 Oct;20(10):1255–1270. [PubMed] [Google Scholar]
  31. Rosenberg J. S., Beeler D. L., Rosenberg R. D. Activation of human prothrombin by highly purified human factors V and X-a in presence of human antithrombin. J Biol Chem. 1975 Mar 10;250(5):1607–1617. [PubMed] [Google Scholar]
  32. Rosenberg R. D., Damus P. S. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973 Sep 25;248(18):6490–6505. [PubMed] [Google Scholar]
  33. Ruderman N. B., Houghton C. R., Hems R. Evaluation of the isolated perfused rat hindquarter for the study of muscle metabolism. Biochem J. 1971 Sep;124(3):639–651. doi: 10.1042/bj1240639. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Simionescu M., Simionescu N., Silbert J. E., Palade G. E. Differentiated microdomains on the luminal surface of the capillary endothelium. II. Partial characterization of their anionic sites. J Cell Biol. 1981 Sep;90(3):614–621. doi: 10.1083/jcb.90.3.614. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES